PMID: 8968014Dec 18, 1996Paper

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group

JAMA : the Journal of the American Medical Association
J D CurbJ Stamler

Abstract

To assess the effect of low-dose, diuretic-based antihypertensive treatment on major cardiovascular disease (CVD) event rates in older, non-insulin-treated diabetic patients with isolated systolic hypertension (ISH), compared with nondiabetic patients. Double-blind, randomized, placebo-controlled trial: the Systolic Hypertension in the Elderly Program (SHEP). Multiple clinical and support centers in the United States. A total of 4736 men and women aged 60 years and older at baseline with ISH (systolic blood pressure [BP], > or = 160 mm Hg; diastolic BP, <90 mm Hg) at baseline, 583 non-insulin-dependent diabetic patients and 4149 nondiabetic patients (4 additional patients not so classifiable were randomized but not included in these analyses). Diabetes mellitus defined as physician diagnosis, taking oral hypoglycemic drugs, fasting glucose level of 7.8 mmol/L or more (> or = 140 mg/dL), or any combination of these characteristics. The active treatment group received a low dose of chlorthalidone (12.5-25.0 mg/d) with a step-up to atenolol (25.0-50.0 mg/d) or reserpine (0.05-0.10 mg/d) if needed. The placebo group received placebo and any active antihypertensive drugs prescribed by patient's private physician for persistently hig...Continue Reading

Associated Clinical Trials

Citations

Feb 5, 1998·Lancet·A J Krentz, A J Evans
Dec 25, 2013·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Patricio López-JaramilloUNKNOWN nombre del Grupo de Expertos de Latinoamérica
Sep 12, 2000·Current Hypertension Reports·A de La Sierra, L M Ruilope
Mar 12, 2009·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Joshua J NeumillerKeith Campbell
Nov 17, 2010·Nature Reviews. Cardiology·Rhonda M Cooper-DeHoffCarl J Pepine
Feb 24, 2001·Clinical Therapeutics·F FreytagUNKNOWN Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group
Apr 12, 2000·Journal of General Internal Medicine·J B Meigs, R S Stafford
Aug 25, 2005·Journal of General Internal Medicine·Michael L Johnson, Hardeep Singh
Mar 20, 2003·Current Diabetes Reports·Christopher A Newton, Philip Raskin
Jun 3, 2005·Current Diabetes Reports·Fadi El-AtatSamy I McFarlane
Mar 20, 2003·Current Diabetes Reports·Nathaniel Winer, James R Sowers
Mar 20, 2003·Current Diabetes Reports·R Komers, S Anderson
Mar 20, 2003·Current Diabetes Reports·Kambiz Kalantarinia, Helmy M Siragy
Apr 29, 2010·Current Diabetes Reports·Swapnil N RajpathakFrank B Hu
Sep 13, 2008·Journal of General Internal Medicine·T Alafia SamuelsFrederick L Brancati
Dec 16, 1998·BMJ : British Medical Journal·E Goyder, L Irwig
Sep 3, 1999·BMJ : British Medical Journal·L E RamsayG Russell
Jul 9, 2002·British Journal of Clinical Pharmacology·Desmond G JohnstonShareen Forbes
Oct 27, 2001·BMJ : British Medical Journal·N F OlivariusP A Pedersen
Oct 31, 2003·BMC Family Practice·Patrick J O'ConnorDonald B Bishop
Apr 21, 2005·PLoS Medicine·Steve MorganLixiang Yan
Dec 21, 2005·Heart·UNKNOWN British Cardiac SocietyUNKNOWN Stroke Association
Feb 20, 2007·Postgraduate Medical Journal·Elisabete Pinto
Sep 8, 2007·Journal of the American Board of Family Medicine : JABFM·Aanand D NaikMark E Kunik
Sep 10, 2008·Archives of Internal Medicine·Richard W GrantBlackford Middleton
Jul 16, 2009·Journal of General Internal Medicine·Usha SubramanianCarol M Mangione
Feb 23, 2010·Journal of General Internal Medicine·Alan J ChristensenGary E Rosenthal
Jun 15, 2011·Journal of General Internal Medicine·R Neal AxonLeonard E Egede
Jan 1, 2010·Integrated Blood Pressure Control·Gerti Tashko, Robert A Gabbay
Jan 30, 2013·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Leigh MacconellLisa Porter
Dec 28, 2002·The American Journal of Geriatric Cardiology·Michael A Weber
Jun 21, 2001·The American Journal of Geriatric Cardiology·Wilbert S. Aronow
Jul 2, 2002·The American Journal of Geriatric Cardiology·G E Sander
Jan 5, 2002·The American Journal of Geriatric Cardiology·Gastone Leonetti, Alberto Zanchetti
Oct 31, 2001·The American Journal of Geriatric Cardiology·R W Schrier
Aug 18, 2009·Current Opinion in Cardiology·Raymond Cartier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.